Global Cancer Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Class;
Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, and Others.By Indication;
Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, and Others.By Therapy;
Immunotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy, and Others.By Cancer Type;
Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Cancer Drugs Market (USD Million), 2021 - 2031
In the year 2024, the Global Cancer Drugs Market was valued at USD 180,948.28 million. The size of this market is expected to increase to USD 300,202.09 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.5%.
Global Cancer Drugs Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 7.5 %
Study Period | 2025 - 2031 |
---|---|
Base Year | 2024 |
CAGR (%) | 7.5 % |
Market Size (2024) | USD 180,948.28 Million |
Market Size (2031) | USD 300,202.09 Million |
Market Concentration | Medium |
Report Pages | 378 |
Major Players
- Roche
- Merck & Co., Inc.
- Novartis
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Johnson & Johnson
- Takeda Pharmaceutical Company
- AbbVie
- Eli Lilly and Company
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Cancer Drugs Market
Fragmented - Highly competitive market without dominant players
The Global Cancer Drugs Market is expanding rapidly, driven by the rising prevalence of cancer and the growing emphasis on advanced treatment options. As cancer becomes more prevalent among chronic diseases, pharmacological therapies are playing a critical role in patient management. More than 50% of individuals receiving cancer treatment now rely on drug therapies, underscoring their importance in clinical care.
Growing Preference for Targeted Treatment Approaches
The industry is shifting toward targeted and precision therapies that offer better outcomes with minimized side effects. Drugs such as monoclonal antibodies and tyrosine kinase inhibitors have gained prominence, making up about 45% of cancer drug utilization. This trend is redefining treatment strategies and facilitating more individualized therapeutic responses.
Rising Popularity of Immune-Based Therapies
Immunotherapies are gaining widespread acceptance for their ability to activate the immune system in targeting cancer cells. Currently, they account for over 30% of drug use in oncology, reflecting a major transformation in treatment approaches. From checkpoint inhibitors to adoptive cell therapies, these drugs are reshaping cancer care protocols.
Healthcare Incentives Enabling Broader Access
Government-led healthcare incentives and insurance coverage policies are making cancer drugs more accessible to the public. Around 35% of cancer-related public programs now offer reimbursement for pharmacological treatments, improving affordability and patient adherence. These developments are crucial in ensuring equitable access to advanced cancer care.
Global Cancer Drugs Market Recent Developments
-
In July 2022, GSK acquired Sierra Oncology, a biopharmaceutical company headquartered in California.
-
In July 2022, AstraZeneca announced its acquisition of TeneoTwo to expand its pipeline for treating hematological cancers.
Segment Analysis
The Global Cancer Drugs Market has been segmented into Drug Class, Indication, Therapy, and Cancer Type, each of which plays a critical role in the treatment and management of various cancer types. Understanding these segments helps in identifying the therapeutic approaches, drugs, and patient groups that drive growth and innovation in the cancer drugs market.
Drug Class is a key segmentation that includes chemotherapy, immunotherapy, targeted therapy, and hormonal therapy, each serving distinct roles in cancer treatment. Chemotherapy drugs are designed to kill rapidly dividing cancer cells but may also affect normal cells, leading to side effects. Immunotherapy uses the body's immune system to fight cancer, offering a targeted approach with fewer side effects compared to chemotherapy. Targeted therapy targets specific molecules involved in cancer cell growth, providing more precise treatment options. Hormonal therapy works by blocking hormones that fuel certain cancers, such as breast and prostate cancer. The diversity of drug classes provides oncologists with a range of treatment options tailored to specific cancer types and patient needs.
Indication in the cancer drugs market refers to the specific conditions or symptoms that a drug is intended to treat. Cancer drugs are used for various cancer types and to address disease stages or other related complications. This includes preventive treatments for high-risk individuals, adjuvant therapy after surgery to prevent recurrence, and palliative care to relieve symptoms and improve the quality of life for advanced cancer patients. Drugs may also be used for metastatic cancers, where cancer has spread to other parts of the body. The market is driven by drugs developed for different indications based on the stage and type of cancer.
Therapy options in the cancer drugs market include monotherapy, where a single drug is used, and combination therapy, which involves using multiple drugs in tandem to increase efficacy. Combination therapies are gaining popularity due to their potential to target cancer from different angles, reducing the likelihood of resistance and improving outcomes. Adjuvant therapies are used in conjunction with primary treatment methods such as surgery or radiation therapy to enhance effectiveness. The choice of therapy depends on the cancer stage, patient condition, and response to previous treatments, making this a crucial segment in determining treatment regimens.
Cancer Type segmentation identifies the specific types of cancer targeted by various drugs. This includes common cancers like lung cancer, breast cancer, prostate cancer, colorectal cancer, and leukemia, as well as rarer forms like pancreatic cancer, melanoma, and sarcoma. Each cancer type requires tailored therapeutic approaches due to differences in tumor biology, genetic mutations, and response to treatment. For example, targeted therapies are particularly effective for cancers with specific genetic mutations, such as HER2-positive breast cancer. As research continues, newer therapies and drugs are being developed for specific cancer types, further enhancing personalized treatment options.
In conclusion, the segmentation of the cancer drugs market by drug class, indication, therapy, and cancer type highlights the variety of treatments available to manage the disease. These segments reflect the growing focus on personalized and targeted therapies, driven by advances in biotechnology, clinical research, and cancer genomics. Understanding these dynamics provides insights into the evolving landscape of cancer care, where precision medicine is increasingly becoming a central strategy in combating the disease.
Global Cancer Drugs Segment Analysis
In this report, the Global Cancer Drugs Market has been segmented by Drug Class, Indication, Therapy, Cancer Type and Geography.
Global Cancer Drugs Market, Segmentation by Drug Class
The Global Cancer Drugs Market has been segmented by Drug Class into Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, and Others.
This segmentation highlights the variety of therapeutic strategies employed in cancer treatment, offering different mechanisms of action based on the drug class used.
Cytotoxic Drugs are among the most widely used in cancer treatment, especially in chemotherapy. These drugs work by directly killing cancer cells or inhibiting their ability to divide. They are often effective against rapidly dividing cells, which is a characteristic of cancerous cells. However, they can also affect healthy, dividing cells, leading to side effects such as hair loss, nausea, and weakened immune function. Cytotoxic drugs are commonly used in the treatment of cancers like leukemia, lymphoma, and breast cancer, and they form the cornerstone of many chemotherapy regimens.
Targeted Drugs have emerged as a more precise approach to cancer treatment. Unlike cytotoxic drugs, which attack both cancerous and healthy cells, targeted drugs are designed to specifically target molecules or pathways involved in cancer cell growth and survival. These drugs are more selective, leading to fewer side effects and improved efficacy in certain types of cancer. Targeted therapies are commonly used in cancers with known genetic mutations, such as HER2-positive breast cancer, EGFR-mutant lung cancer, and BCR-ABL-positive chronic myelogenous leukemia (CML). As the understanding of cancer genetics and molecular biology improves, the number of targeted therapies is expected to grow.
Hormonal Drugs are used in the treatment of hormone-sensitive cancers, such as breast cancer and prostate cancer. These drugs either block the body’s production of certain hormones or interfere with their action, effectively depriving hormone-dependent cancer cells of the signals they need to grow. For example, tamoxifen is commonly used in breast cancer treatment, while anti-androgens are used for prostate cancer. Hormonal therapies are often used as adjuvant treatments after surgery or radiation to reduce the risk of recurrence, or in cases of metastatic disease to slow down cancer progression.
Others in the drug class segment include drugs that do not fit into the traditional categories of cytotoxic, targeted, or hormonal drugs. This category may encompass immunotherapy, gene therapy, and monoclonal antibodies that have unique mechanisms of action. Immunotherapy, for example, stimulates the immune system to recognize and attack cancer cells, while gene therapies aim to repair or replace faulty genes in cancer cells. The growing field of immuno-oncology, which includes checkpoint inhibitors like nivolumab and pembrolizumab, is a major area of focus within this category, offering promising new treatments for cancers that were previously difficult to treat.
In conclusion, the segmentation of the cancer drugs market by drug class reflects the diverse therapeutic options available for cancer treatment. Each drug class provides distinct mechanisms for targeting cancer cells, with ongoing research and clinical trials driving the development of more targeted and personalized therapies. As scientific understanding of cancer biology advances, the market will continue to see the introduction of innovative drugs that offer more effective and less toxic treatment options for patients.
Global Cancer Drugs Market, Segmentation by Indication
The Global Cancer Drugs Market has been segmented by Indication into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, and Others.
This segmentation reflects the varied nature of cancer and the different approaches required to treat each cancer type effectively.
Lung Cancer remains one of the leading indications in the cancer drugs market due to its high incidence and mortality rates. The treatment of lung cancer has evolved significantly, with advancements in targeted therapies, immunotherapies, and chemotherapy regimens. Drugs such as EGFR inhibitors, ALK inhibitors, and immune checkpoint inhibitors have proven to be effective in treating specific subtypes of non-small cell lung cancer (NSCLC). The focus is increasingly on personalized treatments based on the genetic profile of the tumor, enabling more effective and less toxic therapies.
Stomach Cancer is another major indication in the cancer drugs market. Though relatively less common than lung and breast cancers, stomach cancer is often diagnosed at later stages, making treatment challenging. Chemotherapy, targeted therapies such as HER2 inhibitors, and immunotherapies are commonly used to treat advanced-stage gastric cancer. The growing emphasis on molecular profiling of tumors has led to more personalized approaches, improving the effectiveness of treatment and survival rates for patients with stomach cancer.
Colorectal Cancer is one of the most prevalent types of cancer worldwide, with both men and women affected. Treatment for colorectal cancer involves a combination of surgery, chemotherapy, targeted therapies, and, more recently, immunotherapies. Drugs targeting EGFR, VEGF, and PD-1/PD-L1 have become integral to managing advanced colorectal cancer. Immunotherapies and novel drug combinations are being explored in clinical trials to improve outcomes for patients, particularly those with metastatic disease.
Breast Cancer is one of the largest segments in the cancer drugs market, driven by the high incidence of the disease and the availability of various targeted treatments. Breast cancer treatment varies depending on factors such as hormone receptor status, HER2 status, and the stage of the cancer. Hormonal therapies, HER2-targeted therapies, and chemotherapy are commonly used, with immune checkpoint inhibitors and CDK4/6 inhibitors emerging as important treatment options for advanced or metastatic breast cancer. The ongoing focus on precision medicine continues to drive the development of new treatments tailored to individual patients.
Prostate Cancer is another significant indication within the cancer drugs market, particularly among older men. The treatment of prostate cancer includes hormonal therapies, chemotherapy, and targeted therapies. Androgen deprivation therapy (ADT) is commonly used for advanced stages, and recent advances in immunotherapy and PARP inhibitors have shown promise in treating metastatic castration-resistant prostate cancer (mCRPC). As with other cancers, personalized treatment approaches based on genetic and molecular profiling are becoming increasingly important.
Others in the indication segment include less common types of cancer, such as liver cancer, ovarian cancer, kidney cancer, and bladder cancer, among others. These cancers often require specialized treatment regimens, which may include chemotherapy, targeted therapies, immunotherapy, or a combination of approaches. As research progresses, new drugs and treatment strategies for these and rare cancers continue to emerge, driving growth in the market.
In summary, the segmentation by indication underscores the diverse treatment strategies needed for different types of cancer. Each cancer type has its own set of challenges, and ongoing advancements in drug development are helping to address these with more personalized, effective treatments. The market for cancer drugs continues to grow as new therapies are introduced for a wide range of indications, offering hope for improved survival rates and better quality of life for patients.
Global Cancer Drugs Market, Segmentation by Therapy
The Global Cancer Drugs Market has been segmented by Therapy into Immunotherapy, Targeted Therapy, Chemotherapy, Hormone Therapy and Others.
The Global Cancer Drugs Market is a dynamic sector driven by advancements in therapeutic strategies aimed at combating various types of cancer. This market has been strategically segmented by therapy to address specific mechanisms and targets within cancer cells. Immunotherapy, a cutting-edge approach, harnesses the body's immune system to fight cancer cells. It has gained significant traction due to its ability to offer durable responses and fewer side effects compared to traditional treatments like chemotherapy. Key players in this segment are continually innovating to enhance efficacy and broaden the spectrum of cancers that can be effectively treated using immunotherapies.
Targeted therapy represents another pivotal segment in the cancer drugs market, focusing on specific molecules or pathways crucial for cancer cell survival and proliferation. This precision approach allows for tailored treatments that can potentially improve outcomes while minimizing damage to healthy tissues. The development of targeted therapies has been accelerated by advances in molecular biology and genomics, which enable a deeper understanding of cancer biology at the molecular level. As a result, targeted therapies are increasingly becoming a cornerstone in the treatment paradigm for many types of cancers, driving growth and investment in this segment of the market.
Chemotherapy and hormone therapy, although more established, continue to play crucial roles in cancer treatment. Chemotherapy involves the use of drugs to kill or inhibit the growth of cancer cells throughout the body, often used in combination with surgery or radiation therapy. Meanwhile, hormone therapy works by altering hormone levels in the body to slow or stop the growth of hormone-sensitive tumors. These therapies remain integral options, particularly in cases where other treatments may not be suitable or effective. Overall, the segmentation of the global cancer drugs market reflects a diverse landscape of innovative approaches and established therapies, all aimed at improving patient outcomes and advancing the fight against cancer.
Global Cancer Drugs Market, Segmentation by Cancer Type
The Global Cancer Drugs Market has been segmented by Cancer Type into Breast Cancer, Blood Cancer, Gastrointestinal Cancer, Prostate Cancer, Skin Cancer, Lung Cancer and Others.
The Global Cancer Drugs Market has witnessed significant segmentation based on various cancer types, reflecting the diverse nature of oncological treatments and the specific needs of patients. Among the prominent segments is Breast Cancer, which remains a focal point due to its high incidence among women worldwide. The market for breast cancer drugs continues to expand with advancements in targeted therapies and immunotherapies, aimed at improving survival rates and quality of life for patients.
Blood Cancer, encompassing leukemia, lymphoma, and myeloma, represents another crucial segment in the global cancer drugs market. Treatments for blood cancers have evolved rapidly with the introduction of novel therapies such as CAR-T cell therapies and monoclonal antibodies. These advancements have not only prolonged survival but also offered potential cures in certain cases, thereby driving the growth of this segment.
Gastrointestinal Cancer, including cancers of the colon, rectum, stomach, liver, and pancreas, forms a substantial part of the market due to its prevalence and challenging treatment landscape. Therapies for gastrointestinal cancers range from chemotherapy and radiation to targeted therapies tailored to specific genetic mutations. The market growth in this segment is propelled by ongoing research into personalized medicine and the development of innovative drug combinations to combat resistance and improve outcomes for patients.
Global Cancer Drugs Market, Segmentation by Geography
In this report, the Global Cancer Drugs Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Cancer Drugs Market Share (%), by Geographical Region, 2024
In 2023, the global cancer drugs market exhibited significant regional variations in market share, reflecting diverse healthcare landscapes and economic conditions across different parts of the world. North America maintained a dominant position with a substantial market share, primarily driven by advanced healthcare infrastructure, high prevalence of cancer, and robust research and development activities. The United States, in particular, contributed significantly to this region's market share, being home to several leading pharmaceutical companies and research institutions pioneering cancer treatment innovations. The region's strong regulatory framework and high healthcare expenditure also bolstered its leadership in the global cancer drugs market.
Europe continued to hold a considerable share of the global cancer drugs market in 2023, characterized by a sophisticated healthcare system, extensive government funding for healthcare research, and a large patient pool. Countries like Germany, France, and the United Kingdom played pivotal roles in driving market growth, supported by their well-established pharmaceutical industries and healthcare policies that prioritize cancer treatment advancements. The region's emphasis on personalized medicine and adoption of novel therapies further contributed to its substantial market share, making it a key player in the global oncology landscape.
Asia-Pacific emerged as a rapidly growing region in the global cancer drugs market, fueled by increasing incidences of cancer, improving healthcare infrastructure, and rising healthcare spending in countries such as China, Japan, and India. The region's large population base and expanding middle-class with greater access to healthcare services drove the demand for cancer drugs. Additionally, partnerships between local and international pharmaceutical companies for clinical trials and drug development initiatives enhanced Asia-Pacific's market presence. Despite challenges such as varying regulatory landscapes and pricing pressures, the region's growing significance in global oncology research and treatment options continued to shape its increasing market share in 2023.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Cancer Drugs Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
---|---|---|---|---|---|
Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Research and development advancements
- Increasing cancer prevalence
-
Technological innovations in drug delivery - Innovations in drug delivery technologies are reshaping the dynamics of the global cancer drugs market by boosting treatment precision, minimizing harmful side effects, and enhancing patient compliance. Cutting-edge systems such as liposomes, micelles, polymeric carriers, and nanoparticle-based formulations facilitate targeted drug release directly to cancerous tissues. This approach not only strengthens the therapeutic impact but also significantly reduces collateral damage to healthy cells, resulting in improved patient outcomes and fewer adverse reactions.
In addition, the emergence of stimuli-responsive delivery platforms—which activate based on specific tumor conditions like pH level, temperature, or enzyme activity—is accelerating the shift toward more personalized cancer therapies. These smart systems align with the evolving demand for individualized care and open up avenues for the development of advanced drug combinations and novel therapeutics. As pharmaceutical companies intensify investment in next-generation delivery innovations, these advancements are expected to propel long-term market expansion while reinforcing the focus on targeted, efficient, and patient-friendly cancer treatments.
Restraints
- High cost of cancer drugs
- Stringent regulatory requirements
-
Side effects associated with treatments - Adverse effects linked to cancer treatments continue to present a significant challenge to the expansion of the global cancer drugs market. Commonly used therapies such as chemotherapy, targeted therapies, and immunotherapy are often associated with intense side effects, including nausea, extreme fatigue, immune suppression, hair loss, and organ damage. These physical burdens can severely diminish a patient’s quality of life and lead to decreased treatment adherence, which directly impacts therapeutic success and limits market uptake.
Moreover, the variability and unpredictability of side effects among different patients create hurdles in delivering consistent and personalized treatment. The potential for long-term health complications and cumulative toxicity makes both patients and clinicians cautious, particularly in managing vulnerable groups such as the elderly or those with pre-existing conditions. This ongoing concern over safety and tolerability acts as a deterrent to the widespread adoption of advanced cancer drugs, despite their clinical promise and technological sophistication.
Opportunities
- Personalized medicine approaches
- Emerging markets in Asia-Pacific and Latin America
-
Development of targeted therapies - The growing focus on the development of targeted therapies is creating substantial opportunities in the global cancer drugs market. Unlike conventional treatments that affect both healthy and cancerous cells, targeted therapies are designed to interact with specific molecular markers associated with cancer progression. This precision-driven approach reduces damage to normal tissues and improves the overall safety and effectiveness of cancer treatments, making it an increasingly preferred option among clinicians and patients alike.
Advancements in genomic sequencing, molecular diagnostics, and biomarker identification have been key enablers of this trend. These innovations allow researchers to better understand tumor biology and tailor therapies that selectively inhibit cancer cell growth or disrupt critical signaling pathways. As a result, targeted therapies are demonstrating promising outcomes across various cancer types, including breast, lung, and colorectal cancers, thereby broadening their therapeutic scope and market potential.
Pharmaceutical companies are actively investing in R&D for novel monoclonal antibodies, tyrosine kinase inhibitors, and other precision drugs to strengthen their oncology pipelines. In parallel, regulatory agencies are increasingly approving these therapies under accelerated pathways, further supporting their commercial success. The ability to offer customized, less toxic, and more effective treatments is expected to drive widespread adoption, particularly as healthcare systems shift toward value-based and personalized medicine models.
As awareness about the benefits of targeted therapies grows and healthcare providers seek to minimize adverse effects while improving patient outcomes, this segment is poised for rapid expansion. The trend also aligns with the broader transformation of oncology care, where data-driven treatment strategies are becoming the cornerstone of modern cancer management, reinforcing the long-term growth trajectory of the cancer drugs market.
Competitive Landscape Analysis
Key players in Global Cancer Drugs Market include :
- Roche
- Merck & Co., Inc.
- Novartis
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Johnson & Johnson
- Takeda Pharmaceutical Company
- AbbVie
- Eli Lilly and Company
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Indication
- Market Snapshot, By Therapy
- Market Snapshot, By Cancer Type
- Market Snapshot, By Region
- Global Cancer Drugs Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Research and development advancements
- Increasing cancer prevalence
- Technological innovations in drug delivery
- Restraints
- High cost of cancer drugs
- Stringent regulatory requirements
- Side effects associated with treatments
- Opportunities
- Personalized medicine approaches
- Emerging markets in Asia-Pacific and Latin America
- Development of targeted therapies
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Industry Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Cancer Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
- Cytotoxic Drugs
- Targeted Drugs
- Hormonal Drugs
- Others.
- Global Cancer Drugs Market, By Indication, 2021 - 2031 (USD Million)
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Others
- Global Cancer Drugs Market, By Therapy, 2021 - 2031 (USD Million)
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Hormone Therapy
- Others
- Global Cancer Drugs Market, By Cancer Type, 2021 - 2031 (USD Million)
- Breast Cancer
- Blood Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Skin Cancer
- Lung Cancer
- Others
- Global Cancer Drugs Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Cancer Drugs Market, By Drug Class, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Roche
- Merck & Co. Inc.
- Novartis
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Johnson & Johnson
- Takeda Pharmaceutical Company
- AbbVie
- Eli Lilly and Company
- Company Profiles
- Analyst Views
- Future Outlook of the Market